Novo Nordisk reported mostly mild side effects from its experimental weight-loss drug CagriSema, though results upset ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s compe ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

The U.S. Department of Agriculture considers vaccinating poultry against bird flu amidst a major animal-health crisis, with ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...